The FDA approved revakinagene taroretcel (Encelto) as the first treatment for adults with idiopathic macular telangiectasia ...

Patients with moderate to severe papulopustular rosacea have better outcomes with low-dose minocycline than with placebo and ...

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in a fireside chat at the ...

Consider it your chance to have the first look at – and the last word on – all of Vogue’s content. Use precise geolocation ...

The mucus comes from the conjunctiva which is the transparent tissue covering the whites of the eye and internal surface of ...

Rosacea treatment is a marathon — not a sprint — and there’s a need for increased emphasis on a patient-centric approach to ...

You likely wash your face twice a day, and that's exactly what your dermatologist wants you to do. Having rosacea poses an ...

Q4 2024 Earnings Call Transcript February 25, 2025 Tarsus Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Good morning and welcome to Tarsus this year in 2024 financial results conference call. As a reminder, this call is being recorded at this time. I would like to turn the call over to David Nakasone, ...

Continued to advance a robust pipeline. Pursuing the next potentially transformative category in eye care - Ocular Rosacea a ...